Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shore

Showing results (421-430 of 590) with videos related to

Pageof 59
Sort By:
The Oncologist|October 9, 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS TrialNeal D Shore, Maha Hussain, Fred Saad, et al.
Schizophrenia Bulletin|January 1, 1988
Clinical phenomenologyN C Andreasen, D Shore, J D Burke, et al.
Urology|November 28, 2017
Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published DataLawrence I Karsh, Eric T Gross, Christopher M Pieczonka, et al.
Urology|March 26, 2014
Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelixE David Crawford, Neal D Shore, Judd W Moul, et al.
European Urology Oncology|December 24, 2023
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO StudyRonald Tutrone, Fred Saad, Daniel J George, et al.
Eclinicalmedicine|August 21, 2025
Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysisStephen J Freedland, Ugo De Giorgi, Antti Rannikko, et al.
Future Oncology (London, England)|February 8, 2023
Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS studyNeal D Shore, Felipe Cruz, Luke Nordquist, et al.
Prostate Cancer and Prostatic Diseases|March 2, 2024
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancerNeal D Shore, Emmanuel S Antonarakis, Ashley E Ross, et al.
BMC Urology|September 8, 2018
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
BMC Urology|October 5, 2018
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
Pageof 59

Showing results (421-430 of 590) with videos related to

Sort By:
Pageof 59
The Oncologist|October 9, 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS TrialNeal D Shore, Maha Hussain, Fred Saad, et al.
Schizophrenia Bulletin|January 1, 1988
Clinical phenomenologyN C Andreasen, D Shore, J D Burke, et al.
Urology|November 28, 2017
Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published DataLawrence I Karsh, Eric T Gross, Christopher M Pieczonka, et al.
Urology|March 26, 2014
Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelixE David Crawford, Neal D Shore, Judd W Moul, et al.
European Urology Oncology|December 24, 2023
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO StudyRonald Tutrone, Fred Saad, Daniel J George, et al.
Eclinicalmedicine|August 21, 2025
Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysisStephen J Freedland, Ugo De Giorgi, Antti Rannikko, et al.
Future Oncology (London, England)|February 8, 2023
Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS studyNeal D Shore, Felipe Cruz, Luke Nordquist, et al.
Prostate Cancer and Prostatic Diseases|March 2, 2024
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancerNeal D Shore, Emmanuel S Antonarakis, Ashley E Ross, et al.
BMC Urology|September 8, 2018
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
BMC Urology|October 5, 2018
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
Pageof 59